Uveal Melanoma: Refusal of Treatment.

IF 0.9 Q4 OPHTHALMOLOGY
Ocular Oncology and Pathology Pub Date : 2021-10-01 Epub Date: 2021-08-27 DOI:10.1159/000515559
Randy Christopher Bowen, Soto Hansell, Vishal Raval, Jacquelyn M Davanzo, Arun D Singh
{"title":"Uveal Melanoma: Refusal of Treatment.","authors":"Randy Christopher Bowen,&nbsp;Soto Hansell,&nbsp;Vishal Raval,&nbsp;Jacquelyn M Davanzo,&nbsp;Arun D Singh","doi":"10.1159/000515559","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to explore factors for refusing treatment in patients diagnosed with uveal melanoma and their subsequent clinical course.</p><p><strong>Methods: </strong>This study included patients with uveal melanoma who refused standard of care treatment. Patient-reported reasons and pre-existing mental health diagnoses were assessed. The sociodemographic profile was compared with the controls. Ocular survival, metastasis-free survival (MFS), and overall survival (OS) were calculated.</p><p><strong>Results: </strong>Nine patients with uveal melanoma declined ocular treatment (plaque brachytherapy, <i>n</i> = 7 [78%]; enucleation, <i>n</i> = 2 [22%]). The choroidal melanomas were small (<i>n</i> = 1 [11%]), medium (<i>n</i> = 5 [56%]), and large (<i>n</i> = 3 [33%]) in size (COMS criteria). The sociodemographic profile of the study patients was not different from those that accepted treatment. One patient (11%) had pre-existing mental health diagnosis. Five patients (56%) eventually accepted treatment following an average delay of 19 months (range: 4-55 months) due to neovascular glaucoma or severe vision loss. MFS could not be ascertained, and OS was 67% (6/9) at 4.2 years of follow-up (mean).</p><p><strong>Conclusions: </strong>Refusal of initial recommended treatment is associated with poor ocular survival. The small sample size did not allow for an evaluation of the impact on survival.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531830/pdf/oop-0007-0361.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ocular Oncology and Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000515559","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/8/27 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 3

Abstract

Purpose: This study aimed to explore factors for refusing treatment in patients diagnosed with uveal melanoma and their subsequent clinical course.

Methods: This study included patients with uveal melanoma who refused standard of care treatment. Patient-reported reasons and pre-existing mental health diagnoses were assessed. The sociodemographic profile was compared with the controls. Ocular survival, metastasis-free survival (MFS), and overall survival (OS) were calculated.

Results: Nine patients with uveal melanoma declined ocular treatment (plaque brachytherapy, n = 7 [78%]; enucleation, n = 2 [22%]). The choroidal melanomas were small (n = 1 [11%]), medium (n = 5 [56%]), and large (n = 3 [33%]) in size (COMS criteria). The sociodemographic profile of the study patients was not different from those that accepted treatment. One patient (11%) had pre-existing mental health diagnosis. Five patients (56%) eventually accepted treatment following an average delay of 19 months (range: 4-55 months) due to neovascular glaucoma or severe vision loss. MFS could not be ascertained, and OS was 67% (6/9) at 4.2 years of follow-up (mean).

Conclusions: Refusal of initial recommended treatment is associated with poor ocular survival. The small sample size did not allow for an evaluation of the impact on survival.

Abstract Image

葡萄膜黑色素瘤:拒绝治疗。
目的:本研究旨在探讨葡萄膜黑色素瘤患者拒绝治疗的因素及其随后的临床病程。方法:本研究纳入了拒绝标准护理治疗的葡萄膜黑色素瘤患者。评估了患者报告的原因和先前的心理健康诊断。将社会人口统计资料与对照组进行比较。计算眼部生存、无转移生存(MFS)和总生存(OS)。结果:9例葡萄膜黑色素瘤患者眼部治疗下降(斑块近距离治疗,n = 7 [78%];去核,n = 2[22%])。脉络膜黑色素瘤按COMS标准分为小(n = 1[11%])、中(n = 5[56%])和大(n = 3[33%])。研究患者的社会人口学特征与接受治疗的患者并无不同。一名患者(11%)先前有精神健康诊断。由于新生血管性青光眼或严重视力丧失,5名患者(56%)在平均延迟19个月(范围:4-55个月)后最终接受了治疗。MFS无法确定,平均随访4.2年,OS为67%(6/9)。结论:拒绝最初推荐的治疗与眼部生存不良有关。样本量小,无法评估对生存的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.40
自引率
0.00%
发文量
20
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信